α-mouse CD309 (VEGFR-2) (BP0060) | α-mouse CD134 (OX40 ) (BP0031) |
InVivoMab vs. InVivoPlus | ||
Purity level | InVivoMab >95% |
InVivoPlus >95% |
protein aggregates validated at ≤5% | ✔ | |
azide and carrier protein free | ✔ | ✔ |
endotoxin concentration | < 2EU/mg | < 1EU/mg |
validated by immunoblot, FC, or ELISA | ✔ | |
tested for murine pathogens | ✔ | |
available in bulk quantities | ✔ | ✔ |
Antigen | Reactivity | Application | Clone | InVivoMab Catalog |
InVivoPlu Catalog |
4-1BB (CD137) | mouse | in vivo and in vitro 4-1BB stimulation | 3H3 | BE0239 | BP0239 |
4-1BB (CD137) | mouse | in vitro 4-1BB blockade, FC | 17B5 | BE0296 | |
4-1BBL (CD137L) | mouse | in vivo 4-1BBL blockade | TKS-1 | BE0110 | |
B7-1 (CD80) | mouse | in vivo B7-1 blockade, Affinity chromatography | 1G10 | BE0134 | |
BTLA (CD272) | mouse | in vivo BTLA stimulation, in vivo BTLA blockade | 6A6 | BE0132 | |
BTLA (CD272) | mouse | in vivo BTLA+ B cell and CD4 T cell depletion, FC | 6F7 | BE0304 | |
CD19 | mouse | in vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, FC | 1D3 | BE0150 | |
CD19 | human | FC, Functional assays, IF, Chimeric antigen receptor construction | 4G7 | BE0281 | |
CD20 | human/monkey | in vivo B cell depletion in hCD20 Tg mice, IHC-F, IP, FC | 2H7 | BE0276 | |
CD20 | mouse | FC, WB | AISB12 | BE0302 | |
CD28 | mouse | in vitro T cell stimulation/activation, in vivo CD28 blockade | 37.51 | BE0015-1 | |
CD28 | human/monkey | in vitro T cell stimulation/activation, FC, IHC-F | CD28.2 | BE0291 | |
CD40 | mouse | in vivo CD40 activation, in vitro B cell stimulation/activation | FGK4.5/FGK45 | BE0016-2 | |
CD40L (CD154) | mouse | in vivo and in vitro blocking of CD40/CD40L signaling | MR-1 | BE0017-1 | BP0016-2 |
CD40L (CD154) | human/monkey | in vitro and in vivo blocking of CD40/CD40L signaling, IP, FC | 5C8 | BE0292 | BP0017-1 |
CD44 | mouse/human | in vivo CD44 neutralization | IM7 | BE0039 | |
CD44 | human | in vitro CD44 blockade, WB, IF | Hermes-1 | BE0262 | |
CD47 | human/mouse/rat | in vivo CD47 blockade, in vitro CD47 blockade, IF | MIAP410 | BE0283 | |
CD47 (IAP) | mouse | in vivo CD47 blockade, IF | MIAP301 | BE0270 | |
CD80 (B7-1) | mouse | in vivo CD80 blockade, FC | 16-10A1 | BE0024 | |
CD86 (B7-2) | mouse | in vivo CD86 blockade, FC | GL-1 | BE0025 | |
CD96 | mouse | in vivo and in vitro CD96 blocking, FC | 3.3 | BE0337 | |
CD103 | mouse | in vivo CD103 neutralization, IF, FC | M290 | BE0026 | |
CD172a (SIRPα) | mouse | in vivo and in vitro SIRPα blocking, WB, IP, FC | P84 | BE0322 | |
CD209b (SIGN-R1) | mouse | in vivo SIGN-R1 blockade, IHC-F, WB, FC | 22D1 | BE0220 | |
CD276 (B7-H3) | mouse | in vivo B7-H3 blockade, FC | MJ18 | BE0124 | |
CD314 (NKG2D) | mouse | in vivo and in vitro NKG2D blockade, FC | CX5 | BE0334 | |
c-Kit (CD117) | mouse | in vivo mast cell depletion, in vivo c-Kit+ cell depletion, in vitro c-Kit neutralization, IP, FC | ACK2 | BE0293 | |
c-myc | human | WB, ELISA, FC | 9E10 | BE0238 | |
CSF1R (CD115) | mouse | in vivo macrophage depletion, in vitro CSF-R1 neutralization, in vivo monocyte depletion, FC | AFS98 | BE0213 | |
CSF1R (CD115) | human | in vitro CSF1R neutralization, IHC-P, Functional assays, FC | 2-4A5-4 | BE0347 |